Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Clevecord Market Expansion From $ Billion In 2026 To $ Billion In 2030
The expansion observed in the historical timeframe stemmed from factors such as the restricted supply of compatible donors, the initial achievements seen in cord blood transplantation procedures, progress made in stem cell storage techniques, the increasing number of transplant facilities, and a higher occurrence rate of leukemia cases.
The expansion of stem cell therapy applications, better transplant outcomes, the development of cord blood registries, a rising need for oncology treatments, and supportive regulatory environments are fueling growth during the forecast period. Notable trends shaping this period encompass the increasing application of cord blood stem cell transplants, a greater requirement for alternative donor options, the broadening of hematopoietic transplant indications, more widespread use in both pediatric and adult oncology, and the reinforcement of cord blood banking infrastructure.
Download A Free Sample Report For Comprehensive Market Insights:
Clevecord Market Demand Drivers: What Is Fueling Industry Growth?
The projected increase in demand for stem cell therapies is set to propel the clevecord market forward. Stem cell therapy involves using stem cells to repair or replace damaged cells or tissues, addressing conditions like blood disorders, neurodegenerative diseases, and injuries. This rising demand is fueled by progress in regenerative medicine, the expansion of personalized medicine, greater public awareness, and technological advancements. Clevecord is valuable in these therapies due to its high concentration of mesenchymal stem cells, which aid tissue regeneration, immune modulation, and advanced treatment options. For example, in January 2024, the Bioindustry Association (BIA) in the UK reported that, as of October 2023, the UK leads Europe in cell and gene therapy clinical trials with 84 drugs under development, surpassing France (45), Spain (44), and Germany (40). Globally, US companies captured 86% of venture funding for cell and gene therapy in 2022 and are expected to maintain leadership in 2023. Consequently, the growing demand for stem cell therapies is fueling the clevecord market’s expansion.
The clevecord market is anticipated to benefit from rising healthcare expenditure, which is driving its growth. Healthcare expenditure encompasses all spending on healthcare services, products, and activities like prevention, diagnosis, treatment, and health condition management. This spending is increasing due to an aging population, medical technology advancements, a higher prevalence of chronic diseases, and rising costs of pharmaceuticals and medical services. Expenditure on healthcare supports clevecord by advancing cord blood banking, fostering innovative medical therapies, and providing accessible, high-quality stem cell storage. As an illustration, in April 2025, the Office for National Statistics (ONS) in the UK noted that total healthcare expenditure increased by 6.5% nominally and 2.4% in real terms from 2023 to 2024, with healthcare’s GDP share remaining stable at 11.1% in 2024. Thus, the uptick in healthcare expenditure is promoting growth in the clevecord market.
The clevecord market’s growth is expected to be spurred by the expanding global aging population. This demographic group consists of a larger share of individuals aged 65 and older, driven by longer life expectancy and lower birth rates. The aging population is growing thanks to improved healthcare and living standards that extend lifespans, coupled with declining birth rates in numerous areas. Older individuals require clevecord because stem cell therapies utilizing hematopoietic progenitor cells from cord blood can address age-related blood disorders, cancers, and degenerative diseases, offering regenerative possibilities for those with weakened immune systems and reduced cell repair capabilities. As reported by the World Health Organization (WHO) in October 2025, by 2030, one in six people worldwide will be 60 or older, with this age group’s population expected to double to 2.1 billion by 2050. Therefore, the rising number of older people globally is advancing the clevecord market.
Clevecord Market Segment Outlook: Which Categories Are Expanding The Fastest?
The clevecord market covered in this report is segmented –
1) By Indication: Chronic Myeloid Leukemia (CML), Gastrointestinal Stromal Tumors (GISTs)
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies
3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care
Clevecord Market Key Companies And Competitive Benchmarking
Major companies operating in the clevecord market are Cleveland Cord Blood Center Inc.
Access The Complete Clevecord Market Report:
Clevecord Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the clevecord market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clevecord market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model